Founded in 2010 and listed on the SSE STAR Market in 2019, Jiangsu Bioperfectus Technologies Co., Ltd. (“BioPerfectus”, stock code: 688399.SH) is a National High-Tech Enterprise specializing in in vitro diagnostics, medical testing services, and consumer healthcare.
With a focus on infectious disease testing and women’s and children’s health, BioPerfectus has developed more than 700 diagnostic reagents and automated instruments. Its integrated capabilities span key raw materials, laboratory products, and technical services, supporting clinical diagnostics, public health, and at-home testing.
Building on its multiplex real-time PCR and POCT platforms, the company is expanding into digital PCR, mass spectrometry, and next-generation sequencing, while extending its solutions to early cancer screening, respiratory infections, chronic disease management, and nutrition.
BioPerfectus continues to expand globally through its subsidiaries in Hong Kong, Indonesia, the United States, and Brazil. With 549 international market access certifications, its products are available in more than 100 countries and regions worldwide.